Clinical Trials
785
85 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1880
Active, not recruiting
49
6.2%
Completed
390
49.7%
Enrolling By Invitation
10
1.3%
Not yet recruiting
26
3.3%
Recruiting
107
13.6%
Suspended
9
1.1%
Terminated
110
14.0%
Unknown
22
2.8%
Withdrawn
62
7.9%
No approval data available
- USC-led research published in Cell demonstrates that granulocyte-monocyte progenitors (GMPs) can be extensively expanded and genetically engineered in the laboratory for cancer immunotherapy. - The study overturns the prevailing view that long-term self-renewal is exclusive to hematopoietic stem cells, showing GMPs can self-renew while maintaining their identity. - CAR-engineered GMPs engrafted into bone marrow, continuously generating macrophages that delayed disease progression in mouse models of blood cancer and solid tumors. - The platform also restored infection-fighting ability in mice with chronic granulomatous disease, suggesting applications beyond oncology.
- USC researchers identified the dorsolateral funiculus (DLF) as a precise spinal cord region that encodes bladder fullness, with neural firing climbing from 30 Hz to nearly 100 Hz during filling. - Patterned electrical microstimulation at DLF coordinates triggered coordinated voiding in 91.7% of trials in rats, rising to 100% when the bladder was pre-filled to natural activation volume. - The envisioned closed-loop neuroprosthesis, named BLISS (Bladder-Linked Stimulation System), would restore both the sensation of needing to void and the act itself. - A separate NIH-funded study at USC will use fMRI and diffusion MRI to identify imaging biomarkers that predict which stroke survivors benefit from transcutaneous spinal cord stimulation for urinary incontinence.
- AcuraStem has been awarded a two-year research grant from Target ALS to advance therapeutics targeting SYF2, a pre-mRNA splicing factor that regulates TDP-43 function in amyotrophic lateral sclerosis. - The grant will support mechanistic studies of SYF2 modulation, which has shown promise in preclinical models for restoring normal TDP-43 activity and protecting motor neurons from degeneration. - The research collaboration includes Johns Hopkins University and Mayo Clinic Jacksonville investigators, focusing on TDP-43 dysfunction present in the vast majority of ALS cases. - SYF2 suppression has demonstrated the ability to alleviate TDP-43 pathology and neurodegeneration in ALS models, providing scientific rationale for therapeutic development.
- NeOnc Technologies will host an investor conference call on March 4, 2026, to present initial Phase 1 dose-escalation data from the NEO212-01 clinical trial evaluating their bioconjugated temozolomide platform for CNS malignancies. - The presentation will include safety and toxicity data, dose-escalation observations, pharmacokinetic findings, and planned regulatory next steps from the Phase 1/2 clinical trial. - The company's NEO212 therapeutic is part of a proprietary drug development platform designed to overcome blood-brain barrier challenges and is currently advancing under FDA Fast-Track status. - Distinguished neuro-oncology experts from Duke University and NYU Langone Health will participate as independent Scientific Advisory Board members in the data presentation.
- A phase II randomized clinical trial led by Penn State and USC researchers demonstrated that targeted therapy for the less-impaired arm significantly improved movement and control in chronic stroke survivors with severe paralysis. - The study of 53 participants showed that training the "good" arm resulted in 12% faster completion of dexterity tests, with improvements persisting for at least six months after therapy ended. - This first-of-its-kind evidence-based intervention challenges traditional stroke rehabilitation by addressing the often-overlooked 10-25% loss of motor coordination in the less-impaired arm. - The findings, published in JAMA Neurology, could meaningfully enhance quality of life and reduce caregiver burden for stroke survivors who rely on their functional arm for daily tasks.
- A phase II study of 72 patients demonstrated that the combination of cabozantinib and temozolomide achieved a 79.4% progression-free survival rate at 12 weeks in patients with unresectable or metastatic leiomyosarcoma. - The dual-targeting approach yielded a median progression-free survival of 6.3 months and median overall survival of 19.2 months in the leiomyosarcoma cohort. - Treatment was well-tolerated with manageable toxicity profiles, with the most common grade 3-4 adverse events being platelet count decrease (30%) and neutrophil count decrease (18%). - The combination therapy targets both VEGF and MET pathways simultaneously, representing a novel therapeutic strategy for this rare and aggressive soft tissue sarcoma.
- President Trump issued an executive order to expedite cannabis reclassification from Schedule I to Schedule III under the U.S. Controlled Substances Act, recognizing medical use and reducing research barriers. - The FDA has received over 800 Investigational New Drug applications for cannabis-derived products, while researchers publish thousands of peer-reviewed cannabis studies annually despite limited clinical trials. - MediPharm Labs, with FDA site registration and proven U.S. clinical trial supply experience, has already supplied materials for over 10 active clinical trials including the NIH-funded LiBBY study. - The reclassification may enable institutional investors previously restricted by Schedule I trafficking clauses to consider research-oriented cannabis companies, potentially increasing pharmaceutical industry investment.
- A tumor-informed ctDNA assay identified triple-negative breast cancer patients with a nearly 30-fold higher risk of distant recurrence following neoadjuvant therapy and surgery. - Among patients with treatment-resistant tumors, those who were ctDNA-negative post-treatment achieved significantly better 3-year survival outcomes comparable to complete responders. - The findings from two major clinical trials suggest ctDNA testing could guide treatment decisions for both escalation in high-risk patients and de-escalation in low-risk cases. - Early ctDNA clearance as soon as 3 weeks into treatment was associated with favorable therapeutic response across all breast cancer receptor subtypes.
- Autobahn Labs, a venture studio focused on transforming academic science into drug discovery programs, has announced a strategic partnership with global pharmaceutical company Astellas Pharma Inc. - The collaboration provides Astellas exclusive investment opportunities in selected drug discovery programs from Autobahn's translational research pipeline, which includes early-stage discoveries from leading academic institutions. - Selected research programs will be advanced through newly formed Program Companies with shared equity interests among Autobahn, Astellas, academic institutions, and founding investigators. - Astellas will receive a right of first negotiation for exclusive licenses to further develop and commercialize intellectual property arising from jointly funded programs.
- Regenerative Patch Technologies has treated the first two patients in a Phase IIb clinical trial testing its CPCB-RPE1 stem cell-based retinal implant for advanced dry age-related macular degeneration. - The Phase I/IIa trial demonstrated promising results with 27% of treated eyes showing greater than 5-letter visual acuity improvement compared to 7% of untreated fellow eyes after a mean follow-up of 36.9 months. - The Phase IIb trial incorporates a cryopreserved formulation of the implant and will test the therapy in patients with less severe disease to confirm its vision-improving potential. - Geographic atrophy affects 10-20% of Americans over 65 and currently has limited treatment options that only slow lesion growth rather than improve vision.
